Research Triangle Park, NC - CivaTech Oncology, Inc., an early stage company developing a novel medical device for the treatment of prostate cancer, has raised $1,000,000 in a Series B private financing round. The Company was founded in 2006 by Robert and Claudia Black (two of the founders of Sicel Technologies) and Suzanne Babcock (former VP of Troxler Electronics) and is headquartered in the Park Research Center in RTP. (more…)
Research Triangle Park, N.C.-CivaTech Oncology, Inc., an early stage company developing a novel medical device for the treatment of prostate cancer, has raised $1,000,000 in a Series B private financing round. (more…)
Wilmington, N.C., Apr 28, 2008 - TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products that implement its proprietary minimally invasive surgical approach to treat degenerative disc disease affecting the lower lumbar region of the spine, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its AxiaLIF 2L(tm), two level percutaneous lumbar fusion system, in the United States. The AxiaLIF 2L(tm) is designed to treat degenerative disc disease at both the L5-S1 and L4-L5 lumbar discs through a single, one and a half inch incision. (more…)
Philadelphia, PA—Quaker BioVentures announced today that it has
closed its second fund with $420 million in total commitments, bringing Quaker BioVentures’ total assets under management to $700 million. Following its successful first $280 million fund, which invested in 24 companies, Quaker will maintain its unique
investment focus on life science companies in the Mid-Atlantic region, an opportunityrich, yet still underserved market. (more…)
Durham, NC– Aldagen, Inc. today announced it has raised $18.4 million in a private round of financing. The financing was obtained from existing investors, including Intersouth Partners, Tullis-Dickerson, Harbert Venture Partners and The Aurora Funds. The company plans to use the proceeds raised in this financing to further advance the development of its four clinical-stage product candidates and for general corporate purposes. (more…)
Durham, NC—A therapy that holds promise for enlisting the immune system in the fight against cancer, HIV and infectious disease just got a shot in the arm. Argos Therapeutics has closed a $35.2 million tranched Series C round led by TVM Capital with participation from new investors Mizuho Capital, Morningside Group and Japan Asia Investment Co. (more…)
Memphis, Tennessee- Innova Memphis Inc., an early-stage investment fund, announced today it has invested in arGentis Pharmaceuticals LLC, a specialty pharmaceutical company based in Memphis. (more…)
Atlanta, GA—Biofisica Inc., an Atlanta-based company specializing in wound care therapy, has obtained a commitment of $2.3 million in financing from investors. The funding will support Biofisica’s continued marketing efforts in the UK and ongoing planning initiatives in the United States. (more…)
Winston-Salem, NC—New jobs and increased activity are expected at the Regenerative Medicine Project at Piedmont Triad Research Park following Wake Forest Baptist’s selection as co-lead of the $85 million Armed Forces Institute for Regenerative Medicine (AFIRM). (more…)
Boca Raton, FL–Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that on April 10, 2008, it had acquired the remaining outstanding equity in its drug discovery holding, ReceptoPharm, Inc. (“Receptopharm”). (more…)
